Adjuvant sunitinib may increase symptoms and reduce quality of life in kidney cancer

A recent article in Annals of Oncology┬áreports new patient-reported outcomes data from the S-TRAC study to suggest that adjuvant sunitinib treatment in patients with a high risk of recurrence of renal cell carcinoma (RCC) was linked to increased symptoms and a worse health-related quality of life (HRQoL) compared with placebo. The S-TRAC study showed that […]

read more

Adjuvant therapy for renal cell carcinoma

The following article is a good review of the data from recent clinical trials of adjuvant targeted therapy for renal cell carcinoma (RCC). Adjuvant therapy is the treatment received after surgery to prevent the cancer from spreading and/or returning. The success of targeted therapies, such as vascular endothelial growth factor (VEGF) inhibitors (sunitinib and pazopanib) […]

read more
Showing all 2 results
  TOP